The targeted oncology drug developer, which counts Bristol Myers Squibb and Celgene as investors, is floating above its range in an upsized offering.

Repare Therapeutics, a Canada-based precision cancer therapy developer backed by pharmaceutical firms Bristol Myers Squibb (BMS) and Celgene, will float today in a $220m initial public offering in the US. The company is issuing 11 million shares on the Nasdaq Global Select Market, having increased that number from 10 million. It priced them at the…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.